Back to top
more

Haemonetics (HAE)

(Real Time Quote from BATS)

$84.32 USD

84.32
34,518

+0.24 (0.29%)

Updated Jun 3, 2024 10:18 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (99 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Align Technologies (ALGN) Secures Updated Medical Device License

by Zacks Equity Research

Align Technologies' (ALGN) Invisalign Palatal Expander system receives an updated medical device license from Health Canada.

Here's Why You Should Buy Neogen (NEOG) Stock Now

by Zacks Equity Research

Investors are optimistic about Neogen (NEOG), owing to product launches and the performance of segments.

Tandem Diabetes (TNDM) Avails Tandem Source in the United States

by Zacks Equity Research

Tandem Diabetes (TNDM) announces the full U.S. launch of Tandem Source, a new diabetes management platform for customers and healthcare providers.

Integra (IART) to Advance ENT Division With New Buyout Deal

by Zacks Equity Research

Integra (IART) will be among the top suppliers of ENT products and technologies following the Acclarent acquisition.

Myriad Genetics' (MYGN) New Partnerships Aid Amid FX Woes

by Zacks Equity Research

Myriad Genetics (MYGN) continues to record strong revenue growth from companion diagnostics, including significant revenue share from its proprietary myChoiceCDx test.

Medtronic (MDT) Expands AI-Driven Care With New Partnership

by Zacks Equity Research

Medtronic's (MDT) expanded collaboration with Cosmo Pharmaceuticals is a strategic step forward in its quest to use AI to improve patient care.

Here's Why You Should Retain Exact Sciences (EXAS) Stock Now

by Zacks Equity Research

Investors are optimistic about Exact Sciences (EXAS) on strong Cologuard adoption and raised guidance.

QIAGEN's (QGEN) Strategic Alliances Aid Amid Macro Woes

by Zacks Equity Research

QIAGEN (QGEN) aims to expand the NGS platform by rapidly scaling up the new Enterprise Genomics Services.

Terumo (TRUMY) Launches AZUR HydroPack in Embolotherapy Space

by Zacks Equity Research

Terumo's (TRUMY) coil system boasts a soft, universal-shaped platinum and hydrogel composition, which sets it apart in the peripheral coil market.

Charles River (CRL) Expands 3D In Vitro Services Via New Deal

by Zacks Equity Research

Charles River (CRL) finalizes agreement with service-based biotechnology company, CELLphenomics.

Here's Why Investors Should Retain ResMed (RMD) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about ResMed (RMD) due to the sustained growth in the SaaS business.

Thermo Fisher (TMO) Launches New Solutions for Clinical Labs

by Zacks Equity Research

Thermo Fisher (TMO) introduces the KingFisher Apex Dx system and Applied Biosystems MagMAX Dx Isolation Kit to improve preanalytical workflows for clinical laboratories.

Edwards Lifesciences (EW) Forwards Growth Strategy and Outlook

by Zacks Equity Research

Edwards Lifesciences' (EW) TAVR remains strong, driven by greater awareness, patient activation and advances in new technologies such as RESILIA.

Are Medical Stocks Lagging Arch Therapeutics (ARTH) This Year?

by Zacks Equity Research

Here is how Arch Therapeutics, Inc. (ARTH) and Haemonetics (HAE) have performed compared to their sector so far this year.

Illumina (ILMN) Expands Globally Despite Macroeconomic Woes

by Zacks Equity Research

The NovaSeq X launch strengthens Illumina's (ILMN) competitive position in high-throughput sequencing.

Walgreens' (WBA) AllianceRx Pharmacy Will Now Distribute XDEMVY

by Zacks Equity Research

Walgreens' (WBA) subsidiary, AllianceRx Walgreens Pharmacy, is one of the four specialty pharmacies selected to distribute XDEMVY.

BrainsWay (BWAY) Strengthens South Korean Foothold With Deep TMS

by Zacks Equity Research

BrainsWay's (BWAY) Deep TMS targets affected brain structures with a magnetic field, stimulating crucial neural networks.

Quest Diagnostics (DGX) & CDC to Assess Hepatitis C Burden

by Zacks Equity Research

Quest Diagnostics (DGX) and CDC expand research collaboration to better understand the Hepatitis C burden in the United States.

Here's Why You Should Retain Boston Scientific (BSX) Now

by Zacks Equity Research

Investors are optimistic about Boston Scientific (BSX) on strong worldwide demand for its GI and pulmonary treatment options and traction in Europe for its next-generation WATCHMAN FLX.

Globus Medical (GMED) Gains From NuVasive Deal, Macro Woes Stay

by Zacks Equity Research

Globus Medical (GMED) witnesses notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.

OrthoPediatrics (KIDS) Introduces Unit for Non-Surgical Bracing

by Zacks Equity Research

OrthoPediatrics (KIDS) continues to diversify its non-surgical offerings with the introduction of the DF2 Brace.

Here's Why You Should Retain National Vision (EYE) Stock Now

by Zacks Equity Research

Investors are optimistic about National Vision's (EYE) stock, banking on comparable store sales growth and a favorable liquidity structure.

Tandem Diabetes (TNDM) Launches Dexcom G7 Integrated t:slim X2

by Zacks Equity Research

Tandem Diabetes' (TNDM) t:slim X2 is the first AID system in the world to feature Dexcom's most advanced CGM technology.

Omnicell's (OMCL) Global Expansion Strong, Macro Issues Ail

by Zacks Equity Research

Omnicell (OMCL) accelerates a shift to cloud-based solutions and tech-enabled services through the launches of Inventory Optimization Service and Central Pharmacy Dispensing Services.

Neogen (NEOG) to Offer Biosecurity Products With New Pact

by Zacks Equity Research

Neogen will be able to highlight its biosecurity and horse health products, like the COMPANION range of cleansers and disinfection solutions, through the latest collaboration.